News
Progress of OREGA Biotech’s CD39 Program : IPH5201 to advance into Phase 2 clinical trial in lung cancer
OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, provides an update on its CD39 program: Innate Pharma announced that IPH5201, the CD39 blocking monoclonal antibody developed in collaboration with...
Diabeloop, Key player in therapeutic AI applied to insulin delivery, announces 70 million euros new financing round to accelerate its international expansion
High-growth diabetes company Diabeloop closes its Series C financing round - led by LBO France, joined by Terumo Corporation, Innovacom and backed by Diabeloop’s historical partners - to power the company’s commercial roll-out and global expansion. Complete press...
Amolyt Pharma Announces Positive Results from First Patient Cohort of Phase 2a Trial of AZP-3601 for the Treatment of Hypoparathyroidism
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced positive results from the first cohort of its clinical proof of concept trial of AZP-3601, which the company is developing as a...
StromaCare has raised €1,500,000 for the development of a new oncology therapy based on the immuno-modulation of the tumor stroma using a monoclonal antibody.
This biotech company based in Lyon announces a fundraising of €1,500,000 from Sham Innovation Santé (Advised by Turenne Groupe), Kreaxi, and Crédit Agricole Création. Complete press release StromaCare
Amoéba: Austria recommends the approval of the biocontrol active substance for the European territory
AMOEBA (FR0011051598 - AMEBA), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces that AGES (Agentur für Gesundheit und...
Amolyt Pharma announces US IND Clearance for the Ongoing Clinical Trial of AZP-3601 in Patients with Hypoparathyroidism
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the ongoing AZP-3601...
Amolyt Pharma announces European Commission has granted Orphan drug designation to AZP-3601 for the treatment of Hypoparathyroidism
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the European Commission has granted Orphan Drug Designation (ODD) to AZP- 3601 for the treatment of hypoparathyroidism. Amolyt...
Amolyt Pharma selected for the French Tech 120 Program
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the company has been selected for the French Tech FT120, a support program for French late-stage startups by the French State....
Gustave Roussy and LXRepair announce a partnership for personalized radiotherapy of cancer
LXRepair, a pioneer in personalized radiotherapy with functional assays measuring DNA repair to predict treatment response, with a clinical proof-of-concept of radiotoxicity prediction in breast and prostate cancer, and Gustave Roussy, Europe's leading cancer center,...
Amolyt Pharma Announces $80 Million Series B Financing led by Sectoral Asset Management and Andera Partners
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the company has closed an $80 million Series B equity financing round. The financing was co-led by Sectoral Asset Management...